The global prostate cancer biomarker Market is estimated at a high CAGR during the forecast period (2021-2028).
More on Spindigit:
- For Low Latency choose nearest location Atlanta, Georgia, for Dedicated and VPS Server Hosting by TheServerHost
- For Low Latency choose nearest location Seattle, Washington for Dedicated and VPS Server Hosting by TheServerHost
- What Are the Benefits an Ecommerce Design Agency Provides?
- Fastest processing with GPU based Russia, Moscow Dedicated and VPS Server Hosting by TheServerHost
- Reasons an Artist Should Submit a Paid or a Free Music Press Release
(Spin Digit Editorial):- Alexander, Arkansas Nov 7, 2021 (Issuewire.com) – Market Overview
Biomarkers are “chemicals” that can be used to detect both normal and pathological bodily processes. Prostate-specific antigen is one of the most well-known (PSA). For decades, the PSA test, which detects abnormally high PSA levels in the blood, has been used to screen for prostate cancer and possibly discover it early.
View full report: https://bit.ly/3ESuxrf
Market Dynamics
The factors driving the global prostate cancer biomarker market growth are the rising incidence of prostate cancer and the increasing awareness regarding diagnostic prostate cancer biomarker usage.
The rising incidence of prostate cancer is expected to drive the global prostate cancer biomarker market growth
Prostate cancer biomarker is the second most frequent cancer among men and the fourth most prevalent cancer in the general population. In 2018, there were 1.3 million new cases. According to GLOBOCAN 2018 estimates, 1,276,106 new cases of prostate cancer were reported worldwide in 2018, with developed nations having a greater prevalence.
Elevated plasmatic levels of prostate-specific antigen (PSA > 4 ng/mL), a glycoprotein usually expressed by prostate tissue, are used to detect many prostate malignancies. However, because men without cancer have been identified with increased PSA levels, a tissue biopsy is the gold standard for confirming the existence of malignancy.
Diagnostic prostate cancer biomarker growth and progression are influenced by diet and physical exercise. Dietary variables are primarily responsible for the reported global and ethnic disparities in prostate cancer biomarker incidence rates. Biomarkers are “chemicals” that can be used to detect both normal and pathological bodily processes. Hence, with prostate cancer’s increasing incidence rate, the screening procedure using prostate biomarkers is also expected to increase.
Segmentation Analysis
Global Prostate Cancer Biomarker Market – By Assay Type
- Urine
- Blood
- Serum
Global Prostate Cancer Biomarker Market – By Category
- Diagnostic Prostate Cancer Biomarker
- Prognostic Prostate Cancer Biomarker
- Stratification Prostate Cancer Biomarker
Global Prostate Cancer Biomarker Market – By Region
- North America
- Europe
- South America
- Asia Pacific
- The Middle East and Africa
Download free sample: https://bit.ly/3oam8bY
Competitive Landscape
The global prostate cancer biomarker market is highly competitive with increasing demand for screening procedures for prostate cancer and increasing diagnostic procedures.
Some major key players in the global prostate cancer biomarker Market are BioVision Inc., QIAGEN N.V., Roche Diagnostics Limited, Beckman Coulter Inc and Myriad Genetics, Sanofi-Aventis, Pfizer Inc, MDx Health
Trending Topics:
Follicular Thyroid Cancer Drug Market, Colorectal Cancer Drugs Market, Peptide Cancer Vaccine Market
Media Contact
DataM Intelligence
+18774414866
India
Source :DataM Intelligence
This article was originally published by IssueWire. Read the original article here.
